What is CARDIOX?
CARDIOX operates as a sophisticated AI-driven biosensing platform, engineered to synthesize multi-modal data streams into actionable health intelligence. The platform distinguishes itself by offering non-invasive metrics such as cuffless blood pressure, hydration tracking, and real-time stress analysis. By bridging the gap between behavioral health and metabolic monitoring, CARDIOX provides a versatile toolkit for diverse stakeholders, ranging from corporate wellness programs to elite athletic organizations. Its ability to facilitate both individual and group-level monitoring positions the company as a critical player in the evolving landscape of digital health and preventative medicine.
How much funding has CARDIOX raised?
CARDIOX has raised a total of $12.6M across 4 funding rounds:
Private Equity
$786K
Debt
$652K
Private Equity
$8M
Unspecified
$3.2M
Private Equity (2009): $786K, investors not publicly disclosed
Debt (2010): $652K, investors not publicly disclosed
Private Equity (2011): $8M, investors not publicly disclosed
Unspecified (2014): $3.2M featuring Reservoir Venture Partners and Early Stage Partners
Key Investors in CARDIOX
Reservoir Venture Partners
Reservoir Venture Partners is a specialized firm operating within the venture capital and private equity sectors, focusing on high-growth potential enterprises.
Early Stage Partners
Early Stage Partners is a venture capital firm established in 2001 that provides strategic capital and operational guidance to technology companies, particularly within the Midwest region.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CARDIOX?
With the recent capital injection, CARDIOX is expected to prioritize the expansion of its sensor modalities and the refinement of its predictive analytics engine. The strategic focus will likely shift toward deepening integration with existing healthcare provider workflows and scaling its enterprise-level monitoring capabilities. As the demand for real-time, data-backed health insights continues to rise, the company is well-positioned to leverage its current funding to capture significant market share in the competitive health-tech ecosystem. Future growth will likely hinge on the successful commercialization of its advanced metrics for broader clinical and consumer applications.
See full CARDIOX company page
